Eric B Haura Selected Research

Anaplastic Lymphoma Kinase

1/2020	A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
12/2017	Polypharmacology-based ceritinib repurposing using integrated functional proteomics.
10/2016	Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.
2/2015	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eric B Haura Research Topics

Disease

90	Neoplasms (Cancer) 03/2024 - 11/2002
79	Lung Neoplasms (Lung Cancer) 10/2023 - 07/2003
48	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 07/2002
16	Adenocarcinoma of Lung 10/2020 - 11/2006
7	Carcinogenesis 03/2015 - 06/2005
6	Neoplasm Metastasis (Metastasis) 01/2023 - 06/2005
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 02/2016
4	Fatigue 01/2022 - 12/2018
4	Melanoma (Melanoma, Malignant) 01/2021 - 01/2017
3	Nausea 01/2023 - 11/2019
3	Sarcoma (Soft Tissue Sarcoma) 01/2018 - 05/2012
3	Adenocarcinoma 01/2015 - 09/2009
2	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 01/2021
2	Residual Neoplasm 09/2023 - 01/2017
2	Vomiting 01/2023 - 11/2019
2	Pneumonia (Pneumonitis) 01/2022 - 12/2011
2	Thrombocytopenia (Thrombopenia) 01/2021 - 08/2012
2	Breast Neoplasms (Breast Cancer) 01/2021 - 11/2012
2	Small Cell Carcinoma 01/2017 - 07/2003
2	Disease Progression 01/2017 - 05/2008
2	Inflammation (Inflammations) 01/2015 - 12/2011
2	Rhabdomyosarcoma 05/2012 - 09/2009
1	Thrombocytosis (Thrombocythemia) 03/2024
1	Primary Myelofibrosis (Myelosclerosis) 03/2024
1	Polycythemia Vera 03/2024
1	Dyspnea (Shortness of Breath) 01/2023
1	Chills 01/2023

Drug/Important Bio-Agent (IBA)

35	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2003
34	Phosphotransferases (Kinase)IBA 10/2023 - 07/2003
21	ErbB Receptors (EGF Receptor)IBA 11/2023 - 07/2003
16	Tyrosine (L-Tyrosine)FDA Link 01/2023 - 07/2003
13	Tyrosine Kinase InhibitorsIBA 10/2023 - 11/2006
13	Biomarkers (Surrogate Marker)IBA 01/2023 - 11/2006
11	Dasatinib (BMS 354825)FDA Link 01/2019 - 06/2006
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 03/2024 - 03/2005
6	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2022 - 09/2007
6	RNA (Ribonucleic Acid)IBA 01/2020 - 03/2005
6	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2019 - 04/2010
5	ProteomeIBA 01/2023 - 10/2008
5	Gefitinib (Iressa)FDA Link 01/2022 - 03/2005
5	CytokinesIBA 11/2019 - 07/2003
4	Transforming Growth Factors (Transforming Growth Factor)IBA 06/2021 - 01/2014
4	Anaplastic Lymphoma KinaseIBA 01/2020 - 02/2015
4	VaccinesIBA 03/2019 - 06/2013
4	LigandsIBA 01/2018 - 01/2006
4	Interleukin-6 (Interleukin 6)IBA 07/2014 - 07/2003
4	Transcription Factors (Transcription Factor)IBA 12/2011 - 03/2005
4	src-Family KinasesIBA 07/2010 - 07/2003
4	Epidermal Growth Factor (EGF)IBA 01/2006 - 11/2002
3	AfatinibIBA 11/2023 - 08/2014
3	osimertinibIBA 11/2023 - 01/2021
3	atezolizumabIBA 10/2023 - 10/2022
3	amivantamab-vmjwIBA 10/2023 - 10/2021
3	EnzymesIBA 01/2023 - 07/2013
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2023 - 02/2014
3	Peptides (Polypeptides)IBA 01/2023 - 04/2010
3	PlatinumIBA 10/2021 - 09/2010
3	PhosphotyrosineIBA 01/2021 - 10/2010
3	Formaldehyde (Formol)FDA Link 10/2020 - 01/2019
3	Histone Deacetylase InhibitorsIBA 11/2019 - 09/2007
3	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 07/2003
3	Adenosine Triphosphate (ATP)IBA 01/2018 - 02/2016
3	Messenger RNA (mRNA)IBA 12/2017 - 11/2012
3	Doxycycline (Periostat)FDA LinkGeneric 10/2016 - 05/2012
3	AZD 6244IBA 10/2016 - 01/2016
3	Docetaxel (Taxotere)FDA Link 01/2014 - 06/2004
2	NivolumabIBA 07/2023 - 01/2021
2	Immune Checkpoint InhibitorsIBA 01/2023 - 11/2019
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022 - 12/2016
2	ParaffinIBA 10/2020 - 01/2019
2	Mitogen-Activated Protein KinasesIBA 01/2018 - 04/2010
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2017 - 09/2010
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2016 - 09/2010
2	ChemokinesIBA 08/2016 - 06/2013
2	desthiobiotin (dethiobiotin)IBA 06/2016 - 02/2016
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2016 - 09/2009
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2016 - 01/2015
2	tyrosine receptor (receptor, tyrosine)IBA 10/2015 - 07/2003
2	siltuximabIBA 07/2014 - 03/2011
2	Neutralizing AntibodiesIBA 07/2014 - 03/2011
2	obatoclaxIBA 01/2014 - 03/2008
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 09/2012 - 08/2009
2	Cisplatin (Platino)FDA LinkGeneric 09/2009 - 03/2008
2	alvocidib (flavopiridol)IBA 06/2004 - 01/2003
1	lorlatinibIBA 10/2023
1	lazertinibIBA 10/2023
1	IpilimumabIBA 07/2023
1	insulin receptor-related receptor (IRR)IBA 01/2023
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 01/2023
1	Glutathione (Reduced Glutathione)IBA 01/2023
1	DiazomethaneIBA 01/2023
1	IsomerasesIBA 01/2023
1	Pregnenolone Carbonitrile (PCN)IBA 01/2023

Therapy/Procedure

36	Therapeutics 03/2024 - 06/2004
13	Drug Therapy (Chemotherapy) 10/2023 - 07/2002
6	Immunotherapy 01/2020 - 10/2003
3	Secondary Prevention 12/2020 - 01/2016
3	Chemoprevention 09/2014 - 06/2010
2	Adjuvant Chemotherapy 12/2016 - 11/2002
2	Precision Medicine 10/2015 - 08/2012